Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
RV144
About the Trial
RV144 randomized 16,402 adult volunteers in Thailand to a prime boost regimen of the ALVAC-HIV canarypox vector vaccine followed by AIDSVAX B/E protein boosts, or placebo. Published in the New England Journal of Medicine in 2009, it found a vaccine efficacy of about 31 percent against HIV acquisition, the first signal that a vaccine could prevent HIV infection at all, though protection was modest and waned over time. Correlates analyses linked protection to antibodies against the V1V2 region of the envelope protein, shaping vaccine design. A modified regimen tested in South Africa, HVTN 702, was stopped in 2020 for lack of efficacy.
Related Trials
Diabetes Prevention Program
The DPP randomized 3,234 people with impaired glucose tolerance to metformin, intensive lifestyle modification, or placebo. Lifest...
LOOK AHEAD
LOOK AHEAD randomized over 5,100 overweight or obese adults with type 2 diabetes to intensive lifestyle intervention targeting 7 p...
WOSCOPS
The West of Scotland Coronary Prevention Study randomized 6,595 healthy men with elevated LDL cholesterol to pravastatin or placeb...
Heart Protection Study
HPS randomized 20,536 UK adults with vascular disease or diabetes to simvastatin 40 mg or placebo regardless of baseline cholester...